Business Description
Protalix BioTherapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US74365A1016
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 1.7 | |||||
Equity-to-Asset | 0.4 | |||||
Debt-to-Equity | 0.78 | |||||
Debt-to-EBITDA | 2.03 | |||||
Interest Coverage | 3.28 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -3.76 | |||||
Beneish M-Score | -1.28 | |||||
WACC vs ROIC |
Growth Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -28.3 | |||||
3-Year EBITDA Growth Rate | 0.9 | |||||
3-Year FCF Growth Rate | 68 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 38.09 | |||||
9-Day RSI | 40.49 | |||||
14-Day RSI | 40.57 | |||||
6-1 Month Momentum % | -33.2 | |||||
12-1 Month Momentum % | -59.36 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.54 | |||||
Quick Ratio | 1.12 | |||||
Cash Ratio | 0.98 | |||||
Days Inventory | 309.29 | |||||
Days Sales Outstanding | 26.91 | |||||
Days Payable | 68.94 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -28 | |||||
Shareholder Yield % | -22.4 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 64.91 | |||||
Operating Margin % | 15.97 | |||||
Net Margin % | 12.69 | |||||
FCF Margin % | -4.02 | |||||
ROE % | 41.07 | |||||
ROA % | 10.86 | |||||
ROIC % | 33.6 | |||||
ROC (Joel Greenblatt) % | 88.64 | |||||
ROCE % | 28.42 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 57 | |||||
PE Ratio without NRI | 57 | |||||
PS Ratio | 1.37 | |||||
PB Ratio | 2.48 | |||||
Price-to-Tangible-Book | 2.48 | |||||
EV-to-EBIT | 5.4 | |||||
EV-to-EBITDA | 4.9 | |||||
EV-to-Revenue | 0.97 | |||||
EV-to-Forward-Revenue | 1.91 | |||||
EV-to-FCF | -26.35 | |||||
Price-to-Graham-Number | 1.18 | |||||
Price-to-Net-Current-Asset-Value | 4.39 | |||||
Earnings Yield (Greenblatt) % | 18.51 | |||||
FCF Yield % | -3.02 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Protalix BioTherapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 60.638 | ||
EPS (TTM) (€) | 0.018 | ||
Beta | -0.16 | ||
Volatility % | 54.53 | ||
14-Day RSI | 40.57 | ||
14-Day ATR (€) | 0.047675 | ||
20-Day SMA (€) | 1.086825 | ||
12-1 Month Momentum % | -59.36 | ||
52-Week Range (€) | 1.009 - 3.1 | ||
Shares Outstanding (Mil) | 73.05 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Protalix BioTherapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Protalix BioTherapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Protalix BioTherapeutics Inc Frequently Asked Questions
What is Protalix BioTherapeutics Inc(FRA:PBDA)'s stock price today?
When is next earnings date of Protalix BioTherapeutics Inc(FRA:PBDA)?
Does Protalix BioTherapeutics Inc(FRA:PBDA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |